Reviewing Vyome (NASDAQ:HIND) and TranS1 (OTCMKTS:BAXSQ)

Vyome (NASDAQ:HIND) and TranS1 (OTCMKTS:BAXSQ) are both manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Earnings and Valuation

This table compares Vyome and TranS1″s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$8.01 million	2.53	-$7.13 million	($433.08)	-0.01
TranS1	N/A	N/A	N/A	N/A	N/A

TranS1 has lower revenue, but higher earnings than Vyome.

Insider and Institutional Ownership

22.1% of Vyome shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vyome and TranS1’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-69.71%	-216.95%	-69.42%
TranS1	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Vyome and TranS1, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	0	0	2	0	3.00
TranS1	0	0	0	0	0.00

Vyome currently has a consensus target price of $15.00, indicating a potential upside of 171.25%. Given Vyome’s stronger consensus rating and higher probable upside, analysts clearly believe Vyome is more favorable than TranS1.

Summary

Vyome beats TranS1 on 6 of the 9 factors compared between the two stocks.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

About TranS1

Baxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company’s other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient’s hip for use in fusion procedures.